Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan

Biomaterials

Volumn 35, Issue 25, 2014, Pages 7157-7171

  Qiao, Hongzhi ^a   Sun, Minjie ^a   Su, Zhigui ^a   Xie, Ying ^a   Chen, Minglei ^a   Zong, Li ^a   Gao, Yahan ^a   Li, Huipeng ^a   Qi, Jianping ^b   Zhao, Qun ^c   Gu, Xiaochen ^d   Ping, Qineng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Catechol derived chitosan; Coordination nanocomplex; Kidney targeting; PH sensitive; Renal fibrosis

Indexed keywords

CHITOSAN; DRUG DELIVERY; METAL IONS;

DRUG DELIVERY SYSTEM; KIDNEY TARGETING; LOW MOLECULAR WEIGHT CHITOSANS; NANOCOMPLEXES; PH SENSITIVE; PHYSIOLOGICAL CONDITION; RENAL FIBROSIS; TISSUE DISTRIBUTIONS;

PHENOLS;

CATECHOL; CHITOSAN; DOXORUBICIN; EMODIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MEGALIN RECEPTOR; METAL ION; RECEPTOR; UNCLASSIFIED DRUG; CATECHOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOFLUORESCENCE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG STABILITY; FLUORESCENCE IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; MALE; MEAN RESIDENCE TIME; MOUSE; NANODEVICE; NONHUMAN; PH; PRIORITY JOURNAL; SHAM PROCEDURE; TEMPERATURE; TISSUE DISTRIBUTION; URETER; URETER OBSTRUCTION; ANIMAL; CHEMISTRY; CONFOCAL MICROSCOPY; DRUG EFFECTS; FIBROSIS; INSTITUTE FOR CANCER RESEARCH MOUSE; KIDNEY; KIDNEY DISEASES; MOLECULAR WEIGHT; PATHOLOGY; PROCEDURES; RAT; TUMOR CELL LINE;

MUS;

ANIMALS; CATECHOLS; CELL LINE, TUMOR; CHITOSAN; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED ICR; MICROSCOPY, CONFOCAL; MOLECULAR WEIGHT; NANOPARTICLES; RATS; TISSUE DISTRIBUTION;

EID: 84902083811     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.04.106     Document Type: Article

References (52)

1. Lerman L.O., Chade A.R. Angiogenesis in the kidney: a new therapeutic target?. Curr Opin Nephrol Hypertens 2009, 18:160-165.
2. Boor P., Ostendorf T., Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010, 6:643-656.
3. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006, 69:213-217.
4. Zeisberg M., Neilson E.G. Mechanisms of tubulointerstitial fibrosis. JAm Soc Nephrol 2010, 21:1819-1834.
5. Zhang Z., Zheng Q., Han J., Gao G., Liu J., Gong T., et al. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials 2009, 30:1372-1381.
6. Zhong Y.F., Deng Y.Y., Chen Y.P., Chuang P.Y., He J.C. Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int 2013, 84:1108-1118.
7. Yuan X.P., He X.S., Wang C.X., Liu L.S., Fu Q. Triptolide attenuates renal interstitial fibrosis in rats with unilateral ureteral obstruction. Nephrology (Carlton) 2011, 16:200-210.
8. Li X., Liu W., Wang Q., Liu P., Deng Y., Lan T., et al. Emodin suppresses cell proliferation and fibronectin expression via p38MAPK pathway in rat mesangial cells cultured under high glucose. Mol Cell Endocrinol 2009, 307:157-162.
9. Wang Q.L., Tao Y.Y., Yuan J.L., Shen L., Liu C.H. Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-beta1 signal transduction pathway invivo and invitro. BMC Cell Biol 2010, 11:31.
10. Tao X., Lipsky P.E. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am 2000, 26:29-50. viii.
11. Wang S., Chen T., Chen R., Hu Y., Chen M., Wang Y. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies. Int J Pharm 2012, 430:238-246.
12. Dolman M.E., Harmsen S., Storm G., Hennink W.E., Kok R.J. Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 2010, 62:1344-1357.
13. Prakash J., de Borst M.H., van Loenen-Weemaes A.M., Lacombe M., Opdam F., van Goor H., et al. Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharm Res 2008, 25:2427-2439.
14. Kodaira H., Tsutsumi Y., Yoshioka Y., Kamada H., Kaneda Y., Yamamoto Y., et al. The targeting of anionized polyvinylpyrrolidone to the renal system. Biomaterials 2004, 25:4309-4315.
15. Mathias C.J., Hubers D., Low P.S., Green M.A. Synthesis of [(99m)Tc]DTPA-folate and its evaluation as a folate-receptor-targeted radiopharmaceutical. Bioconjug Chem 2000, 11:253-257.
16. Mi P., Cabral H., Kokuryo D., Rafi M., Terada Y., Aoki I., et al. Gd-DTPA-loaded polymer-metal complex micelles with high relaxivity for MR cancer imaging. Biomaterials 2013, 34:492-500.
17. Macconi D., Chiabrando C., Schiarea S., Aiello S., Cassis L., Gagliardini E., et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. JAm Soc Nephrol 2009, 20:123-130.
18. Novio F., Simmchen J., Vázquez-Mera N., Amorín-Ferré L., Ruiz-Molina D. Coordination polymer nanoparticles in medicine. Coord Chem Rev 2013, 257:2839-2847.
19. Cabral H., Nishiyama N., Kataoka K. Supramolecular nanodevices: from design validation to theranostic nanomedicine. Acc Chem Res 2011, 44:999-1008.
20. Fabriciova G., Sanchez-Cortes S., Garcia-Ramos J.V., Miskovsky P. Surface-enhanced Raman spectroscopy study of the interaction of the antitumoral drug emodin with human serum albumin. Biopolymers 2004, 74:125-130.
21. Shen L., Zhang H.-Y., Ji H.-F. Atheoretical study on Cu (II)-chelating properties of curcumin and its implications for curcumin as a multipotent agent to combat Alzheimer's disease. JMol Struc-Theochem 2005, 757:199-202.
22. Yuan Z.X., Zhang Z.R., Zhu D., Sun X., Gong T., Liu J., et al. Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan. Mol Pharm 2009, 6:305-314.
23. Wang X., Du Y., Fan L., Liu H., Hu Y. Chitosan-metal complexes as antimicrobial agent: synthesis, characterization and structure-activity study. Polym Bull 2005, 55:105-113.
24. Hong S., Yang K., Kang B., Lee C., Song I.T., Byun E., et al. Hyaluronic acid catechol: a biopolymer exhibiting a pH-dependent adhesive or cohesive property for human neural stem cell engineering. Adv Funct Mater 2013, 23:1774-1780.
25. Ling D., Park W., Park Y.I., Lee N., Li F., Song C., et al. Multiple-interaction ligands inspired by mussel adhesive protein: synthesis of highly stable and biocompatible nanoparticles. Angew Chem Int Ed Engl 2011, 50:11360-11365.
26. Guo S., Wang Y., Miao L., Xu Z., Lin C.M., Zhang Y., et al. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 2013, 7:9896-9904.
27. Ryu J.H., Lee Y., Kong W.H., Kim T.G., Park T.G., Lee H. Catechol-functionalized chitosan/pluronic hydrogels for tissue adhesives and hemostatic materials. Biomacromolecules 2011, 12:2653-2659.
28. Ren D., Yi H., Zhang H., Xie W., Wang W., Ma X. Apreliminary study on fabrication of nanoscale fibrous chitosan membranes in situ by biospecific degradation. JMemb Sci 2006, 280:99-107.
29. Mo R., Sun Q., Xue J., Li N., Li W., Zhang C., et al. Multistage pH-responsive liposomes for mitochondrial-targeted anticancer drug delivery. Adv Mater 2012, 24:3659-3665.
30. Xiong Y., Jiang W., Shen Y., Li H., Sun C., Ouahab A., et al. Apoly(γ, l-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. Biomaterials 2012, 33:7182-7193.
31. Xing L., Zheng H., Che S. ApH-responsive cleavage route based on a metal-organic coordination bond. Chemistry 2011, 17:7271-7275.
32. Graham J.M. Isolation of lysosomes from tissues and cells by differential and density gradient centrifugation. Curr Protoc Cell Biol 2001, 7:3.6.1-3.6.21.
33. Lin Y., Li Y., Wang X., Gong T., Zhang L., Sun X. Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine. JControl Release 2013, 167:148-156.
34. Huang Q., Lu G., Shen H.M., Chung M.C., Ong C.N. Anti-cancer properties of anthraquinones from rhubarb. Med Res Rev 2007, 27:609-630.
35. Srinivas G., Babykutty S., Sathiadevan P.P., Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 2007, 27:591-608.
36. Chan T.M., Leung J.K., Tsang R.C., Liu Z.H., Li L.S., Yung S. Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. Kidney Int 2003, 64:519-533.
37. Wang R., Wan Q., Zhang Y., Huang F., Yu K., Xu D., et al. Emodin suppresses interleukin-1β induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK. Life Sci 2007, 80:2481-2488.
38. Paz T., Jana N.R. First derivative spectrophotometry for individual and simultaneous determination of magnesium(II) and copper(II) using emodin(1,3,8-trihydroxy-6-methylanthraquinone) as reagent. Talanta 1993, 40:1519-1524.
39. Bao L., Wang Y., Chang A., Minto A.W., Zhou J., Kang H., et al. Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. JAm Soc Nephrol 2007, 18:811-822.
40. Pang M., Kothapally J., Mao H., Tolbert E., Ponnusamy M., Chin Y.E., et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2009, 297:F996-F1005.
41. Slater K. Cytotoxicity tests for high-throughput drug discovery. Curr Opin Biotechnol 2001, 12:70-74.
42. de Oliveira D.M., Pitanga B.P., Grangeiro M.S., Lima R.M., Costa M.F., Costa S.L., et al. Catechol cytotoxicity invitro: induction of glioblastoma cell death by apoptosis. Hum Exp Toxicol 2010, 29:199-212.
43. Pillai C.K.S., Paul W., Sharma C.P. Chitin and chitosan polymers: chemistry, solubility and fiber formation. Prog Polym Sci 2009, 34:641-678.
44. Wang K., Ma X., Shao D., Geng Z., Zhang Z., Wang Z. Coordination-induced assembly of coordination polymer submicrospheres: promising antibacterial and invitro anticancer activities. Cryst Growth Des 2012, 12:3786-3791.
45. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002, 13:47-58.
46. Huang Y., He L., Liu W., Fan C., Zheng W., Wong Y.S., et al. Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials 2013, 34:7106-7116.
47. Orlando R.A., Rader K., Authier F., Yamazaki H., Posner B.I., Bergeron J.J., et al. Megalin is an endocytic receptor for insulin. JAm Soc Nephrol 1998, 9:1759-1766.
48. Malmo J., Sorgard H., Varum K.M., Strand S.P. siRNA delivery with chitosan nanoparticles: molecular properties favoring efficient gene silencing. JControl Release 2012, 158:261-268.
49. Campbell R.C., Ruggenenti P., Remuzzi G. Halting the progression of chronic nephropathy. JAm Soc Nephrol 2002, 13(Suppl.3):S190-S195.
50. Li L. Use of emodin in preparation of antagonistic TGF beta-1 and medicines to prevent tissues from fibrosis 2005, Patent CN1582905.
51. Shia C.S., Hou Y.C., Tsai S.Y., Huieh P.H., Leu Y.L., Chao P.D. Differences in pharmacokinetics and exvivo antioxidant activity following intravenous and oral administrations of emodin to rats. JPharm Sci 2010, 99:2185-2195.
52. Zhu B., Lin Y., Zhu C.F., Zhu X.L., Huang C.Z., Lu Y., et al. Emodin inhibits extracellular matrix synthesis by suppressing p38 and ERK1/2 pathways in TGF-beta1-stimulated NRK-49F cells. Mol Med Rep 2011, 4:505-509.